Gladstone Institutional Advisory LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Gladstone Institutional Advisory LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,069 shares of the medical research company’s stock after selling 1,921 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Thermo Fisher Scientific were worth $1,974,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. CBIZ Investment Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares in the last quarter. Highline Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at $30,000. Capital A Wealth Management LLC grew its stake in Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after purchasing an additional 66 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. increased its holdings in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TMO shares. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. Evercore ISI restated an “outperform” rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Monday. Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $621.70.

Thermo Fisher Scientific Trading Down 0.6%

NYSE TMO opened at $616.97 on Thursday. The firm’s fifty day moving average price is $579.34 and its 200 day moving average price is $514.40. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $628.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market capitalization of $231.80 billion, a price-to-earnings ratio of 35.64, a price-to-earnings-growth ratio of 4.08 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific declared that its board has initiated a share buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other news, EVP Frederick M. Lowery sold 6,912 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the transaction, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,271 shares of company stock valued at $86,507,282 in the last 90 days. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.